<DOC>
	<DOCNO>NCT00285402</DOCNO>
	<brief_summary>The purpose migraine prevention study evaluate efficacy safety AST-726 moderate severe migraine patient one two dos compare placebo compare baseline period measure reduction number migraine day .</brief_summary>
	<brief_title>Efficacy Safety Clinical Trial Intranasal AST-726 Prevention Migraine</brief_title>
	<detailed_description>Migraine patient may experience repeat migraine attack , last four hour three day . Each attack characterize severe pain , typically one side head often involve number symptom , include pain pulsate throb quality , nausea vomiting , sensitivity light sound , visual disturbance aura . Currently management migraine may either acute treatment prophylaxis . Acute migraine treatment aim abort reverse already present migraine symptom acute administration medicine triptans , whereas migraine prophylaxis aim reduce frequency severity migraine attack time chronic medication . The overall protocol design outcome measurement study follow guideline duration recommend International Headache Society prophylaxis study migraine medication . The study ARPH-CL-03 multicenter , randomize , double-blind , three parallel group design moderate severe migraine patient assess ability daily administration AST-726 one two dos reduce number headache day 4 week period patient receive placebo . AST-726 placebo self-administered intranasal spray daily 12 week . Among efficacy safety assessment , patient ask collect information daily migraine diary . Patients instruct allow use acute migraine medication study .</detailed_description>
	<mesh_term>Headache</mesh_term>
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Migraine without Aura</mesh_term>
	<mesh_term>Migraine Aura</mesh_term>
	<criteria>Primary 1 . Has migraine headache without aura accord International Headache Society guideline ( Committee , 2004 ) . 2 . Has migraine least 6 month prior study enrollment period . 3 . Migraines begin age 50 . 4 . Has 2 10 attack per month great equal 3 migraine day per month last 3 month prior study enrollment . 5 . Has 2 10 attack 30 day Baseline Period . Additional inclusion criterion protocol Primary 1 . Has headache equal great 18 day per month . 2 . Has use migraine medication ( e.g. , topiramate , betablockers ) prophylactic use within 60 day prior study enrollment . 3 . Has excessive use acute migraine medication ( e.g. , triptans , dihydroergotamine [ DHE ] ) great 15 day per month . 4 . Has take nitroglycerinecontaining medication within 60 day prior study enrollment . 5 . Failed 3 clinical study effective migraine prevention medication due uncontrolled migraine . Additional exclusion criterion protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>Migraine</keyword>
	<keyword>Migraine prophylaxis</keyword>
	<keyword>Migraine prevention</keyword>
	<keyword>Chronic migraine treatment</keyword>
</DOC>